ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round

ImmuPharma PLC (AIM:IMM, FRA:25I), the specialist drug discovery and development company, says it is actively progressing partnering discussions for its lead autoimmune technology platform, P140, as its primary strategic focus for 2026. The update came in a chairman's letter to shareholders following approval of two fundraising resolutions at a general meeting.